Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marja van de Bovenkamp

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Cytotherapy|October 18, 2018
Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapyCharlotte DE Wolf, Marja VAN DE Bovenkamp, Marcel Hoefnagel
Cytotherapy|March 31, 2018
Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapyCharlotte de Wolf, Marja van de Bovenkamp, Marcel Hoefnagel
Cytotherapy|May 2, 2017
Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapyCharlotte de Wolf, Marja van de Bovenkamp, Marcel Hoefnagel
Journal of Hepatology|July 11, 2006
Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitroMarja van de Bovenkamp, Geny M M Groothuis, Dirk K F Meijer, et al.
Regulatory Toxicology and Pharmacology : RTP|January 3, 2012
A structured approach to Exposure Based Waiving of human health endpoints under REACH developed in the OSIRIS projectHans Marquart, Tim Meijster, Marja Van de Bovenkamp, et al.
Regulatory Toxicology and Pharmacology : RTP|August 18, 2010
Exposure-based waiving under REACHTheo Vermeire, Marja van de Bovenkamp, Yuri Bruinen de Bruin, et al.
The Journal of Antimicrobial Chemotherapy|April 2, 2003
APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitroCândida F Pereira, Judith T M L Paridaen, Marja van de Bovenkamp, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 25, 2005
Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieuMarja van de Bovenkamp, Geny M M Groothuis, Annelies L Draaisma, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 21, 2007
Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cellsTeresa Gonzalo, Leonie Beljaars, Marja van de Bovenkamp, et al.
Antiviral Research|May 28, 2003
Aspirin-like molecules that inhibit human immunodeficiency virus 1 replicationCândida F Pereira, Judith T M L Paridaen, Karla Rutten, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Cytotherapy|October 18, 2018
Regulatory perspective on in vitro potency assays for human dendritic cells used in anti-tumor immunotherapyCharlotte DE Wolf, Marja VAN DE Bovenkamp, Marcel Hoefnagel
Cytotherapy|March 31, 2018
Regulatory perspective on in vitro potency assays for human T cells used in anti-tumor immunotherapyCharlotte de Wolf, Marja van de Bovenkamp, Marcel Hoefnagel
Cytotherapy|May 2, 2017
Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapyCharlotte de Wolf, Marja van de Bovenkamp, Marcel Hoefnagel
Journal of Hepatology|July 11, 2006
Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitroMarja van de Bovenkamp, Geny M M Groothuis, Dirk K F Meijer, et al.
Regulatory Toxicology and Pharmacology : RTP|January 3, 2012
A structured approach to Exposure Based Waiving of human health endpoints under REACH developed in the OSIRIS projectHans Marquart, Tim Meijster, Marja Van de Bovenkamp, et al.
Regulatory Toxicology and Pharmacology : RTP|August 18, 2010
Exposure-based waiving under REACHTheo Vermeire, Marja van de Bovenkamp, Yuri Bruinen de Bruin, et al.
The Journal of Antimicrobial Chemotherapy|April 2, 2003
APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitroCândida F Pereira, Judith T M L Paridaen, Marja van de Bovenkamp, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 25, 2005
Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieuMarja van de Bovenkamp, Geny M M Groothuis, Annelies L Draaisma, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 21, 2007
Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cellsTeresa Gonzalo, Leonie Beljaars, Marja van de Bovenkamp, et al.
Antiviral Research|May 28, 2003
Aspirin-like molecules that inhibit human immunodeficiency virus 1 replicationCândida F Pereira, Judith T M L Paridaen, Karla Rutten, et al.
Pageof 1